LUCD Lucid Diagnostics Inc

$LUCD Here is objective evidence that Esoguard is in a class of their own. Concert had to create a new category "Evidence-based BE and EC diagnostic algorithmic tests" and Esoguard is the only product in that category. No Endosign, nothing else. If they can get broad coverage, the whole market is theirs.

$LUCD I had a $25K CD mature today. Can you guess what I did with the money? At this point, I'm buying because I believe in the fundamental value of Esoguard. The clinical data are flawless, all of the guidelines are aligned (ACG, AGA, NCCN), and all of the KOLs supportive. It's a life saving tool to screen patients who wouldn't otherwise be screened, and allows GI clinics to grow their endoscopy business. It addresses a cancer that is skyrocketing in incidence. Margins are 90%, pricing is solid, and the TAM is absolutely enormous. Somehow, someway, this becomes worth more than $100M.

$LUCD Do you want to feel better about holding your shares? I sold 3k shares of AMD at $13 and it just hit a new high of $658. Sometimes, it’s just about patience and waiting for the plan to come together! Ugh!😩

$LUCD Lucid effectively has national coverage for Medicare patients RIGHT NOW by sending tests to the new CLIA lab in Texas. How is the market not realizing this? Here is another precedent for this pathway - Aspira stated in a recent SEC filing that because their tests are performed in Texas, that "Novitas Solutions essentially provides national coverage for patients enrolled in Medicare." https://www.sec.gov/Archives/edgar/data/926617/000149315225004349/forms-1a.htm? Aspira has an LCD with Novitas, but Novitas is very clear that in the absence of an LCD or NCD, they cover based on reasonable and necessary guidelines. We have strong evidence for reasonable and necessary which continues to be validated by professional societies and LBMs like Concert. For a long time, Lucid was throttling test volume growth due to lack of coverage. Now Lucid sales reps can go wild selling to the Medicare population. In other words, this is where the rubber meets the road. Test volume and revenue should start to increase in Q4 2026.

$LUCD Well, this is interesting ... I was in the mountains of N.C. without internet for the past week. Consequently, I sold all my stocks last week before leaving because I knew I couldn’t monitor them. As luck would have it, I logged on yesterday and found a blue light special staring me in the face! No explicable/specific reason for this sell-off. So, I basically got a 2 for 1 special! 🤷‍♀️🙏

$LUCD , October 01, 2026 Recommendations Needham sees no reason for Lucid Diagnostics selloff today LUCD | 12:16 PM Needham says the firm spoke to Lucid Diagnostics to understand possible reasons for today's selloff. Management is not aware of news or other factors that would justify the pullback, and highlighted Lucid's recent press release about reimbursement progress, the analyst tells investors in a research note. As such, Needham is a buyer of the stock on today's selloff. It keeps a Buy rating on Lucid Diagnostics with a $3 price target. The stock in midday trading is down 27% to 55c. Related Articles

$LUCD my office manager with over 30 years of medicare billing experience predicts if everything went at planned with Medicare we will be paid by this Thursday via Novitas Solutions. She explained that they should have consecutively batched a smaller number of claims to test for problems. Then when it is happening as planned you open the floodgates. For listening to past Lucid discussions that was exactly their plan and I'm sure that is what they did. While software catches errors in coding and helps fix it near immediately it is also very likely due to the extreme importance of getting this right they consulted with multiple medicare, molecular diagnostic, and Novatis consultants to make sure they got it right. I'm ready for the good news.

$LUCD Yesterday I had a nice conversation with a physician friend of mine. Yes, he is also invested here. We discussed what stands between 500m and 20B for Lucid. To get to 500M we need to become the future standard of care, which is more than apparent that is the direction that we are headed. Once we are the standard of care it's to the Billions with 20B being just a matter of time.

$LUCD we are now currently billing $1938 per test to medicare expecting reimbursement....let that sink in for a minute.

$LUCD Trading below $1 does not mean delisting or reverse split. Nasdaq allows qualifying companies up to 360 days to regain compliance. A favorable MolDX decision, stronger earnings, new contracts, or Texas clarity could quickly push LUCD above $1, making this a temporary setback and potentially an exceptional buy the dip opportunity. 💎🙌

$LUCD - I hope you don’t mind, but I asked AI to comment on your post below. As expected , another great find by you!

$LUCD guys if this stock God willing works out, can we find the next stick together lol I developed a trauma bond with the members of this board over this stock loool met a lot of smart people here that know there stuff would love to continue this

$LUCD I added more today like an addict. The share price is too cheap not to average down a bit. Nothing has really changed and we're in a waiting game. Just my opinion based on what we know. Just trying to be patient (although being deep in the red on this has tested me many times). Still willing to give this a bit more time to play out. Medical space is tough.

$LUCD Big, big news. "Lucid will begin submitting Medicare claims this month under EsoGuard's PLA code, 0114U, for tests performed at its Texas laboratory." That's an excellent stopgap as we wait for MolDX.

$LUCD Why does everyone think we need a RS? We have 180 days from now to get to a buck. Plenty of time to get LCD news.

$LUCD I started buying in the $.80 range and now I have my cost down to $.54 a share . So if you do believe in the stock, this would be a great entry point. Good luck enjoy the ride you paid for the popcorn 

$LUCD Back on 6/4 I put the odds at: 25% June 50% by end of August 70% by end of September. September isn’t over yet. Today’s news doesn’t mean MolDX has made its decision. But Medicare billing is now moving forward through the Texas lab while the MolDX reconsideration continues in California. Sometimes the door opens. Sometimes you find another door. I still like where we’re standing.

$LUCD - I’ve researched Endosign vs Esoguard previously. While it’s never good to have new competition come into your market, my take is that Esoguard has and will strongly exploit its first mover advantage here. Endosign will not be commercially viable with Medicare and commercial insurance coverage for approximately another 2 years. We saw how long it is taking to get Esoguard approved…unless they undercut the price, I don’t see this as a significant competitive threat for years. IMHO

$LUCD Bought 20k more, will keep adding 20k on each .05 drop. Its pretty cheap, they do need to raise capital but, this is ridiculous its not in death spiral financing yet, and they have a potential source of ramp up on revenue in the interim. Seems excessive.

$LUCD vastly inferior product (swallowable sponge) .... But any chance these results presented last week could be contributing for the move .... https://www.businesswire.com/news/home/20261014716448/en/Cyted-Health-Announces-Positive-U.S.-Clinical-Validation-Data-for-the-EndoSign-Barretts-Esophagus-Test